Other
Hypersensitivity
0
Pipeline Programs↗
4
Active Trials↗
7
Companies Involved↗
Hypersensitivity is an early-stage landscape with 0 programs across 7 companies. The most active players are GSK, Ono Pharmaceutical Co. Ltd, Merck & Co..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
55
clinical trials
Completed41 · 75%
Unknown status6 · 11%
Recruiting3 · 5%
Terminated3 · 5%
Approved for marketing1 · 2%
Active, not recruiting1 · 2%
Clinical Trials
Trial Activity
55 trials
Effectiveness of Resin-Based Desensitizer and Laser, Compared to Fluoride Varnish in Management of Dentine Hypersensitivity in Non-carious Cervical Lesions
Active, not recruiting·—·Phase 2/3·NCT07113847·84 enrolled
A Phase I/II Dose Escalation Study of Intradermal gp160 to Evaluate Safety, Delayed Type Hypersensitivity (Skin Test) Responses and Immunogenicity in Asymptomatic HIV Seropositive Patients With More Than 400 CD4+ Cells
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000667·20 enrolled
Asparaginase Encapsulated in Erythrocytes for Patients With ALL and Hypersensitivity to PEG-asparaginase
Completed·—·Phase 2·NCT03267030·55 enrolled
Clinical of Hypersensitivity Reduction Efficacy on Two Toothpastes
Completed·—·Phase 3·NCT06937697·87 enrolled
Efficacy of Seventh Generation Bonding Agents as Short-Term Desensitizers Among Patients With Hypersensitivity
Completed·—·Phase 3·NCT04225247·105 enrolled
Page 1 of 4
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)